Among the 204 patients with RA, administered DMARDs were distributed as follows: 80 patients received MTX (30.1%), 51 patients were treated with JAK inhibitors (19.2%), 45 patients with TNF inhibitors (16.9%) and 28 individuals with RTX (10.5%). Here, TNF is linked to rheumatoid arthritis.